Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173155 | 1.00 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL1259148 | 0.87 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL1173514 | 0.87 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL1173160 | 0.87 | OPRD1 (0.34) | OPRD1 | |
| SCHEMBL2594066 | 0.85 | OPRD1 (0.33) | OPRD1 | |
| SCHEMBL2594067 | 0.85 | OPRD1 (0.33) | OPRD1 | |
| SCHEMBL1173784 | 0.83 | OPRD1 (0.33) | OPRD1 | |
| SCHEMBL2585666 | 0.81 | OPRD1 (0.33) | OPRD1 | |
| SCHEMBL15467620 | 0.78 | OPRD1 (0.31) | OPRD1 | |
| SCHEMBL7709887 | 0.78 | OPRD1 (0.31) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242943-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | SIENA BIOTECH S.P.A. (IT) | 2016-01-26 | — | — | US | disclosed |
| US-9242943-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | SIENA BIOTECH S.P.A. (IT) | 2016-01-26 | — | — | US | disclosed |
| US-9242943-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | SIENA BIOTECH S.P.A. (IT) | 2016-01-26 | — | — | US | disclosed |
| EP-2665713-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | disclosed |
| WO-2012098064-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098064-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | OPRD1 2826/4885 |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | OPRD1 1835/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | OPRD1 1870/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | OPRD1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.